Outgoing CEO Carolyn Starrett to transition as Senior Advisor following a tenure marked by global growth and data leadership
Flatiron Health has announced that Nathan Hubbard will take over as Chief Executive Officer, succeeding Carolyn Starrett. Starrett, who has led the company since 2021, will transition into a senior advisory role after nearly a decade of helping guide Flatiron through substantial growth and transformation. Hubbard brings more than two decades of experience across the biopharmaceutical, healthcare, and data-driven industries, positioning him well to lead Flatiron into its next chapter.
Health Technology Insights: St. Croix Hospice to Acquire Mayo Clinic Hospice in Wisconsin
Hubbard’s expertise spans strategic vision, commercial acumen, and strong operational leadership. He has previously held multiple senior roles where he played a key part in shaping commercial strategies, scaling global operations, and fostering innovation. Known for his mission-driven approach and ability to navigate complex markets, Hubbard’s leadership is expected to strengthen Flatiron’s growth trajectory and global influence in oncology research and care.
Starrett joined Flatiron in 2016, leaving behind a legacy defined by strategic focus and customer-centered innovation. Under her leadership, Flatiron Horizon, the company’s real-world data platform, expanded from 400,000 to more than 5.5 million patients. She launched the evidence services business, enabling biopharmaceutical partners to gain faster, more flexible insights, and oversaw the company’s expansion into Europe and Japan. The OncoEMR electronic health record system grew to serve more than 4,500 U.S. providers, and Flatiron’s data contributed to over 1,800 research publications, reshaping oncology care and research.
Health Technology Insights: Kelly Roberts Joins CoreCare to Lead AI in Reimbursement
During Starrett’s tenure, Flatiron nearly doubled its revenue and developed a scalable, sustainable business model, cementing its leadership in oncology evidence generation. Reflecting on the leadership transition, Starrett said, “Leading Flatiron for the last four and a half years has been the highlight of my career. We are currently in an extremely strong position, and I have faith that the company will speed up its journey towards its full potential with Nathan at the helm. During his five-year tenure at Flatiron, Nathan has built our international business and presence from the ground up, broadened and strengthened our partnerships with leading biopharmaceutical companies, and played a crucial role in shaping our strategic vision.”
Roche, a long-standing partner of Flatiron, expressed its support for the change in leadership. Thomas Schinecker, CEO of Roche, commented, “Nathan’s entrepreneurial spirit, operational acumen, and close alignment with Flatiron’s mission make him the right leader to propel the business forward. Flatiron plays an increasingly vital role in advancing oncology innovation, and I am confident that under Nathan’s leadership, the company will continue to shape the future of cancer research and care.”
Health Technology Insights: OrbiMed Raises $1.86 Billion for Healthcare Royalty and Credit Fund V
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
